Wits RHI 060 (ADVANCE): A 96-week Randomised, Phase 3 Non-inferiority Study of DTG + TAF + FTC Compared with DTG + TDF + FTC and EFV + TDF+FTC in Patients Infected with HIV-1 Starting First-line Antiretroviral Therapy.


 The primary objective of this study is to demonstrate the non-inferiority of dolutegravir (DTG) and tenofovir alafenamide fumarate (TAF) plus emtricitabine (FTC) when compared with DTG and tenofovir disoproxil fumarate (TDF) plus FTC or compared with efavirenz (EFV) and TDF plus FTC in the first-line treatment of patients infected with human immunodeficiency virus (HIV) 1 as determined by the proportion of patients in each regimen with undetectable plasma HIV-1 RNA levels (<50 copies/mL) at Week 48.   


Professor Francois Venter, Principal Investigator
Prof Lee Fairlie, Sub investigator
Dr Faeezah Patel, Sub Investigator
Dr Elizea Horne, Sub Investigator

Latest Update

May 2022

For more details about the ADVANCE Study please email

Research and Policy Briefs


Stay up to date

Get updates on news, resources, events and happenings from Wits RHI.